Atrial fibrillation associated with systemic lupus erythematosus and use of methylprednisolone
Systemic lupus erythematosus is known to have cardiac manifestations consisting of pericarditis, myocarditis, endocarditis, and coronary vasculitis. Pericarditis is the most common cardiac manifestation of systemic lupus erythematosus. Myocarditis may be suspected in patients presenting with unexpla...
Gespeichert in:
| Veröffentlicht in: | American journal of therapeutics 2001-07, Vol.8 (4), p.303-305 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 305 |
|---|---|
| container_issue | 4 |
| container_start_page | 303 |
| container_title | American journal of therapeutics |
| container_volume | 8 |
| creator | Aslam, A K Vasavada, B C Sacchi, T J Khan, I A |
| description | Systemic lupus erythematosus is known to have cardiac manifestations consisting of pericarditis, myocarditis, endocarditis, and coronary vasculitis. Pericarditis is the most common cardiac manifestation of systemic lupus erythematosus. Myocarditis may be suspected in patients presenting with unexplained tachycardia, conduction disturbances, unexplained systolic dysfunction with or without heart failure, or arrhythmias. The development of arrhythmias in systemic lupus erythematosus could be secondary to pericarditis, myocarditis, or ischemia caused by coronary vasculitis. The development of atrial fibrillation in systemic lupus erythematosus is not commonly reported. There have been few reports on the patients developing atrial fibrillation after being started on methylprednisolone therapy. Described here is a case of the development of atrial fibrillation in a newly diagnosed 37-year-old patient with systemic lupus erythematosus who was started on intravenous methylprednisolone therapy. |
| doi_str_mv | 10.1097/00045391-200107000-00013 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1097_00045391_200107000_00013</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>11441330</sourcerecordid><originalsourceid>FETCH-LOGICAL-c226t-e20c47b1a6b969c7294abd96176be1f1181cc2b2f4b8f73f715395aaf3ca07423</originalsourceid><addsrcrecordid>eNpFkNtKxDAQhnOhuOvqK0heoJpJ0qa9XBZPsOCN3lqSNGEj6YEkRfr2RnfVi2H4fvgH5kMIA7kF0og7QggvWQMFJQSIyFjkAXaG1hnLgoqqXKHLGD9ySmvgF2gFwDkwRtbofZuCkx5bp4LzXiY3DljGOGonk-nwp0sHHJeYTO809vM0R2zCkg6ml2mMmeTQ4TkaPFrcm3RY_BRMN7g4-nEwV-jcSh_N9Wlv0NvD_evuqdi_PD7vtvtCU1qlwlCiuVAgK9VUjRa04VJ1TQWiUgYsQA1aU0UtV7UVzArIH5dSWqYlEZyyDaqPd3UYYwzGtlNwvQxLC6T91tT-amr_NLU_mnL15lidZtWb7r94csS-ALsQZz4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Atrial fibrillation associated with systemic lupus erythematosus and use of methylprednisolone</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Aslam, A K ; Vasavada, B C ; Sacchi, T J ; Khan, I A</creator><creatorcontrib>Aslam, A K ; Vasavada, B C ; Sacchi, T J ; Khan, I A</creatorcontrib><description>Systemic lupus erythematosus is known to have cardiac manifestations consisting of pericarditis, myocarditis, endocarditis, and coronary vasculitis. Pericarditis is the most common cardiac manifestation of systemic lupus erythematosus. Myocarditis may be suspected in patients presenting with unexplained tachycardia, conduction disturbances, unexplained systolic dysfunction with or without heart failure, or arrhythmias. The development of arrhythmias in systemic lupus erythematosus could be secondary to pericarditis, myocarditis, or ischemia caused by coronary vasculitis. The development of atrial fibrillation in systemic lupus erythematosus is not commonly reported. There have been few reports on the patients developing atrial fibrillation after being started on methylprednisolone therapy. Described here is a case of the development of atrial fibrillation in a newly diagnosed 37-year-old patient with systemic lupus erythematosus who was started on intravenous methylprednisolone therapy.</description><identifier>ISSN: 1075-2765</identifier><identifier>DOI: 10.1097/00045391-200107000-00013</identifier><identifier>PMID: 11441330</identifier><language>eng</language><publisher>United States</publisher><subject>Adult ; Anti-Inflammatory Agents - administration & dosage ; Anti-Inflammatory Agents - adverse effects ; Atrial Fibrillation - chemically induced ; Female ; Humans ; Injections, Intravenous ; Lupus Erythematosus, Systemic - drug therapy ; Methylprednisolone - administration & dosage ; Methylprednisolone - adverse effects</subject><ispartof>American journal of therapeutics, 2001-07, Vol.8 (4), p.303-305</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c226t-e20c47b1a6b969c7294abd96176be1f1181cc2b2f4b8f73f715395aaf3ca07423</citedby><cites>FETCH-LOGICAL-c226t-e20c47b1a6b969c7294abd96176be1f1181cc2b2f4b8f73f715395aaf3ca07423</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11441330$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aslam, A K</creatorcontrib><creatorcontrib>Vasavada, B C</creatorcontrib><creatorcontrib>Sacchi, T J</creatorcontrib><creatorcontrib>Khan, I A</creatorcontrib><title>Atrial fibrillation associated with systemic lupus erythematosus and use of methylprednisolone</title><title>American journal of therapeutics</title><addtitle>Am J Ther</addtitle><description>Systemic lupus erythematosus is known to have cardiac manifestations consisting of pericarditis, myocarditis, endocarditis, and coronary vasculitis. Pericarditis is the most common cardiac manifestation of systemic lupus erythematosus. Myocarditis may be suspected in patients presenting with unexplained tachycardia, conduction disturbances, unexplained systolic dysfunction with or without heart failure, or arrhythmias. The development of arrhythmias in systemic lupus erythematosus could be secondary to pericarditis, myocarditis, or ischemia caused by coronary vasculitis. The development of atrial fibrillation in systemic lupus erythematosus is not commonly reported. There have been few reports on the patients developing atrial fibrillation after being started on methylprednisolone therapy. Described here is a case of the development of atrial fibrillation in a newly diagnosed 37-year-old patient with systemic lupus erythematosus who was started on intravenous methylprednisolone therapy.</description><subject>Adult</subject><subject>Anti-Inflammatory Agents - administration & dosage</subject><subject>Anti-Inflammatory Agents - adverse effects</subject><subject>Atrial Fibrillation - chemically induced</subject><subject>Female</subject><subject>Humans</subject><subject>Injections, Intravenous</subject><subject>Lupus Erythematosus, Systemic - drug therapy</subject><subject>Methylprednisolone - administration & dosage</subject><subject>Methylprednisolone - adverse effects</subject><issn>1075-2765</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkNtKxDAQhnOhuOvqK0heoJpJ0qa9XBZPsOCN3lqSNGEj6YEkRfr2RnfVi2H4fvgH5kMIA7kF0og7QggvWQMFJQSIyFjkAXaG1hnLgoqqXKHLGD9ySmvgF2gFwDkwRtbofZuCkx5bp4LzXiY3DljGOGonk-nwp0sHHJeYTO809vM0R2zCkg6ml2mMmeTQ4TkaPFrcm3RY_BRMN7g4-nEwV-jcSh_N9Wlv0NvD_evuqdi_PD7vtvtCU1qlwlCiuVAgK9VUjRa04VJ1TQWiUgYsQA1aU0UtV7UVzArIH5dSWqYlEZyyDaqPd3UYYwzGtlNwvQxLC6T91tT-amr_NLU_mnL15lidZtWb7r94csS-ALsQZz4</recordid><startdate>200107</startdate><enddate>200107</enddate><creator>Aslam, A K</creator><creator>Vasavada, B C</creator><creator>Sacchi, T J</creator><creator>Khan, I A</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>200107</creationdate><title>Atrial fibrillation associated with systemic lupus erythematosus and use of methylprednisolone</title><author>Aslam, A K ; Vasavada, B C ; Sacchi, T J ; Khan, I A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c226t-e20c47b1a6b969c7294abd96176be1f1181cc2b2f4b8f73f715395aaf3ca07423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adult</topic><topic>Anti-Inflammatory Agents - administration & dosage</topic><topic>Anti-Inflammatory Agents - adverse effects</topic><topic>Atrial Fibrillation - chemically induced</topic><topic>Female</topic><topic>Humans</topic><topic>Injections, Intravenous</topic><topic>Lupus Erythematosus, Systemic - drug therapy</topic><topic>Methylprednisolone - administration & dosage</topic><topic>Methylprednisolone - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aslam, A K</creatorcontrib><creatorcontrib>Vasavada, B C</creatorcontrib><creatorcontrib>Sacchi, T J</creatorcontrib><creatorcontrib>Khan, I A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>American journal of therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aslam, A K</au><au>Vasavada, B C</au><au>Sacchi, T J</au><au>Khan, I A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Atrial fibrillation associated with systemic lupus erythematosus and use of methylprednisolone</atitle><jtitle>American journal of therapeutics</jtitle><addtitle>Am J Ther</addtitle><date>2001-07</date><risdate>2001</risdate><volume>8</volume><issue>4</issue><spage>303</spage><epage>305</epage><pages>303-305</pages><issn>1075-2765</issn><abstract>Systemic lupus erythematosus is known to have cardiac manifestations consisting of pericarditis, myocarditis, endocarditis, and coronary vasculitis. Pericarditis is the most common cardiac manifestation of systemic lupus erythematosus. Myocarditis may be suspected in patients presenting with unexplained tachycardia, conduction disturbances, unexplained systolic dysfunction with or without heart failure, or arrhythmias. The development of arrhythmias in systemic lupus erythematosus could be secondary to pericarditis, myocarditis, or ischemia caused by coronary vasculitis. The development of atrial fibrillation in systemic lupus erythematosus is not commonly reported. There have been few reports on the patients developing atrial fibrillation after being started on methylprednisolone therapy. Described here is a case of the development of atrial fibrillation in a newly diagnosed 37-year-old patient with systemic lupus erythematosus who was started on intravenous methylprednisolone therapy.</abstract><cop>United States</cop><pmid>11441330</pmid><doi>10.1097/00045391-200107000-00013</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1075-2765 |
| ispartof | American journal of therapeutics, 2001-07, Vol.8 (4), p.303-305 |
| issn | 1075-2765 |
| language | eng |
| recordid | cdi_crossref_primary_10_1097_00045391_200107000_00013 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adult Anti-Inflammatory Agents - administration & dosage Anti-Inflammatory Agents - adverse effects Atrial Fibrillation - chemically induced Female Humans Injections, Intravenous Lupus Erythematosus, Systemic - drug therapy Methylprednisolone - administration & dosage Methylprednisolone - adverse effects |
| title | Atrial fibrillation associated with systemic lupus erythematosus and use of methylprednisolone |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T06%3A05%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Atrial%20fibrillation%20associated%20with%20systemic%20lupus%20erythematosus%20and%20use%20of%20methylprednisolone&rft.jtitle=American%20journal%20of%20therapeutics&rft.au=Aslam,%20A%20K&rft.date=2001-07&rft.volume=8&rft.issue=4&rft.spage=303&rft.epage=305&rft.pages=303-305&rft.issn=1075-2765&rft_id=info:doi/10.1097/00045391-200107000-00013&rft_dat=%3Cpubmed_cross%3E11441330%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/11441330&rfr_iscdi=true |